share_log

The Recent Pullback Must Have Dismayed Bide Pharmatech Co., Ltd. (SHSE:688073) Insiders Who Own 47% of the Company

The Recent Pullback Must Have Dismayed Bide Pharmatech Co., Ltd. (SHSE:688073) Insiders Who Own 47% of the Company

最近的回調一定讓擁有該公司47%股份的Bide Pharmatech有限公司(SHSE: 688073)內部人士感到沮喪
Simply Wall St ·  02/01 06:50

Key Insights

關鍵見解

  • Bide Pharmatech's significant insider ownership suggests inherent interests in company's expansion
  • 53% of the business is held by the top 3 shareholders
  • Institutional ownership in Bide Pharmatech is 17%
  • Bide Pharmatech的大量內部所有權表明了公司擴張的固有利益
  • 53% 的業務由前三名股東持有
  • Bide Pharmatech的機構所有權爲17%

If you want to know who really controls Bide Pharmatech Co., Ltd. (SHSE:688073), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 47% to be precise, is individual insiders. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

如果你想知道誰真正控制了Bide Pharmatech有限公司(SHSE: 688073),那麼你必須看看其股票登記處的構成。持有公司股份最多的集團是內部人士,準確地說約爲47%。換句話說,該集團將從對公司的投資中獲得最多(或損失最大)。

As a result, insiders as a group endured the highest losses after market cap fell by CN¥516m.

結果,在市值下降5.16億元人民幣之後,內部人士整體遭受了最大的損失。

In the chart below, we zoom in on the different ownership groups of Bide Pharmatech.

在下圖中,我們放大了Bide Pharmatech的不同所有權群體。

Check out our latest analysis for Bide Pharmatech

查看我們對 Bide Pharmatech 的最新分析

ownership-breakdown
SHSE:688073 Ownership Breakdown January 31st 2024
SHSE: 688073 所有權明細 2024 年 1 月 31 日

What Does The Institutional Ownership Tell Us About Bide Pharmatech?

關於Bide Pharmatech,機構所有權告訴我們什麼?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

許多機構根據近似於當地市場的指數來衡量自己的表現。因此,他們通常會更多地關注主要指數中包含的公司。

We can see that Bide Pharmatech does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Bide Pharmatech's earnings history below. Of course, the future is what really matters.

我們可以看到,Bide Pharmatech確實有機構投資者;他們持有該公司很大一部分股票。這表明專業投資者有一定的信譽。但是我們不能僅僅依靠這個事實,因爲機構有時會像所有人一樣進行不良投資。如果多家機構同時改變對股票的看法,你可能會看到股價快速下跌。因此,值得在下面查看Bide Pharmatech的收益記錄。當然,未來才是真正重要的。

earnings-and-revenue-growth
SHSE:688073 Earnings and Revenue Growth January 31st 2024
SHSE: 688073 2024 年 1 月 31 日收益和收入增長

Hedge funds don't have many shares in Bide Pharmatech. Looking at our data, we can see that the largest shareholder is Lan Dai with 33% of shares outstanding. With 14% and 5.5% of the shares outstanding respectively, Long Dai and Lishui Xinxi Enterprise Management Partnership Enterprise (Limited Partnership) are the second and third largest shareholders. Long Dai, who is the second-largest shareholder, also happens to hold the title of Chief Executive Officer.

對沖基金在Bide Pharmatech的股票不多。從我們的數據來看,我們可以看到最大的股東是Lan Dai,已發行股份的33%。龍戴和麗水新喜企業管理合夥企業(有限合夥)分別佔已發行股份的14%和5.5%,是第二和第三大股東。第二大股東戴龍也恰好擁有首席執行官的頭銜。

To make our study more interesting, we found that the top 3 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company.

爲了使我們的研究更有趣,我們發現前三名股東擁有公司的多數股權,這意味着他們足夠強大,足以影響公司的決策。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

研究機構所有權是衡量和篩選股票預期表現的好方法。通過研究分析師的情緒也可以達到同樣的目的。有相當數量的分析師在報道該股,因此了解他們對未來的總體看法可能很有用。

Insider Ownership Of Bide Pharmatech

Bide Pharmatech的內部所有權

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

儘管內部人士的確切定義可能是主觀的,但幾乎每個人都認爲董事會成員是內部人士。公司管理層對董事會負責,後者應代表股東的利益。值得注意的是,有時高層管理人員自己也是董事會成員。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多數人認爲內部所有權是積極的,因爲這可能表明董事會與其他股東關係良好。但是,在某些情況下,過多的權力集中在該群體中。

Our information suggests that insiders maintain a significant holding in Bide Pharmatech Co., Ltd.. Insiders have a CN¥1.7b stake in this CN¥3.6b business. We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling.

我們的信息表明,內部人士持有Bide Pharmatech有限公司的大量股份。內部人士在這項36億元的業務中持有17億元人民幣的股份。我們可以說這表明了與股東的一致性,但值得注意的是,該公司仍然很小;一些內部人士可能已經創立了該公司。你可以點擊這裏查看這些內部人士是否在買入或賣出。

General Public Ownership

一般公有制

The general public-- including retail investors -- own 16% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

包括散戶投資者在內的公衆擁有該公司16%的股份,因此不容忽視。雖然這個團體不一定能做主,但它肯定會對公司的運營方式產生真正的影響。

Private Company Ownership

私人公司所有權

It seems that Private Companies own 18%, of the Bide Pharmatech stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

看來私營公司擁有Bide Pharmatech股票的18%。私營公司可能是關聯方。有時,內部人士通過控股私營公司而對上市公司擁有權益,而不是以個人身份擁有權益。儘管很難得出任何寬泛的結論,但值得注意的是,這是一個需要進一步研究的領域。

Next Steps:

後續步驟:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For example, we've discovered 2 warning signs for Bide Pharmatech (1 makes us a bit uncomfortable!) that you should be aware of before investing here.

我覺得看看究竟誰擁有一家公司非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。例如,我們發現了 Bide Pharmatech 的 2 個警告信號(1 個讓我們有點不舒服!)在這裏投資之前,您應該注意這一點。

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

歸根結底,未來是最重要的。您可以訪問這份關於公司分析師預測的免費報告。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論